Industry landscapes
The companies, capital and talent shaping life sciences in India. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
A few useful ratios bring the size of this ecosystem into perspective.
290 of 2,471 tracked companies have open roles.
467 of 2,471 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 938 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 30.9% of disclosed capital, while 81.1% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $44.73M | 128 | 51 |
| 2017 | $112.58M | 141 | 69 |
| 2018 | $211.92M | 148 | 72 |
| 2019 | $101.44M | 164 | 85 |
| 2020 | $707.92M | 191 | 96 |
| 2021 | $224.86M | 176 | 107 |
| 2022 | $421.16M | 143 | 99 |
| 2023 | $175.95M | 127 | 73 |
| 2024 | $273.89M | 124 | 86 |
| 2025 | $231.26M | 50 | 61 |
Share of all disclosed company funding.
1,148 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Kotak Alternate Asset Managers.
Backed by Alkemi Growth Capital and Sanjay Arora and others.
Backed by .
Backed by Elev8 and Orchid Asia Group.
Backed by .
Backed by Indian Angel Network.
Backed by Ashish Kacholia and Lashit Sanghvi and others.
Backed by We Founder Circle.
Backed by Temasek and Motilal Oswal Financial Services.
Backed by Moringa and Gandaraditya Chola and others.
Backed by LeapFrog Investments and HealthQuad and others.
Backed by LeapFrog Investments and Sofina and others.
Backed by Novo Holdings and Sofina and others.
Backed by Maj Invest and Novo Holdings and others.
Backed by HDFC and HDFC Life and others.
Backed by Anil Manibhai Naik and Vipul Chandra and others.
Backed by Elev8 and Orchid Asia Group.
Backed by Orbimed.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 1041 reporting entities from 1274 eligible matches.
Sum of reporting-entity revenue; not India market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
522 of 1041 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 1041 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Serum Institute of India ↗U80903PN1984PTC032945 | ₹9,715.0 crore | ₹4,630.0 crore | +47.7% | — | ₹48,678.0 crore |
| Herbalife ↗U51909KA1998PTC026098 | ₹8,275.0 crore | ₹1,045.8 crore | +12.6% | — | ₹1,301.6 crore |
| Medtronic ↗U33110MH1993PTC204814 | ₹2,638.9 crore | ₹136.8 crore | +5.2% | — | ₹2,014.5 crore |
| Dr.Morepen ↗L24231HP1984PLC006028 | ₹1,554.5 crore | ₹101.6 crore | +6.5% | — | ₹1,721.2 crore |
| Indian Immunologicals ↗U72200TG1999PLC032666 | ₹1,459.6 crore | ₹469.9 crore | +32.2% | — | ₹2,212.4 crore |
| Bharat Biotech ↗U24230TG1996PLC023232 | ₹1,379.5 crore | ₹450.6 crore | +32.7% | — | ₹6,131.1 crore |
| Nuziveedu Seeds ↗U74120TG2008PLC074583 | ₹968.4 crore | ₹213.4 crore | +22.0% | — | ₹1,958.2 crore |
| MedGenome ↗U73100KA2013PLC084414 | ₹329.9 crore | ₹57.7 crore | +17.5% | — | ₹280.4 crore |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the India companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
24 of the 2,471 companies on this page carry a measured traffic record (1%); these are the largest of those, by monthly visits. The median among them is 235,038 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Kapivakapiva.in | 3,401,285 | 46 | 98.6% |
| Plixplixlife.com | 1,717,120 | 47 | 96.8% |
| OZivaoziva.in | 820,875 | 44 | 96.1% |
| Little Joysourlittlejoys.com | 727,145 | 38 | 97.5% |
| Man Mattersmanmatters.com | 590,366 | 46 | 89.2% |
| Midutymiduty.in | 374,104 | 32 | 93.9% |
| Cochlearcochlear.com | 356,360 | 45 | 75.6% |
| Tynortynorstore.com | 346,234 | 40 | 94.9% |
| LifeCelllifecell.in | 302,371 | 44 | 83.6% |
| Rasayanam Ayurvedarasayanam.in | 271,092 | 32 | 94.5% |
Visits and authority are third-party web estimates, not company-reported figures.
126 of these companies (5.1%) publish at least one Android app — 225 apps in all, carrying 18.1M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Man Matters: Hair, Beard, SkinMan Matters | 5.9M | 4.6 | Health & Fitness |
| PlixlifePlix | 2.8M | — | Health & Fitness |
| Be Bodywise Women\'s Health AppBe Bodywise | 2.1M | 4.9 | Health & Fitness |
| Little Joys: Kids\' Health AppLittle Joys | 1.7M | — | Health & Fitness |
| KapivaKapiva | 1.3M | — | Shopping |
| Mylab CoviSelfMylab Discovery Solutions | 988.3K | — | Health & Fitness |
| OZivaOZiva | 914.3K | — | Health & Fitness |
| AyusCareAyuslab | 612.7K | — | Medical |
| Dr Morepen Sync Sugar & BP AppDr.Morepen | 244.5K | — | Health & Fitness |
| Gold ClubNuziveedu Seeds | 106.8K | — | Productivity |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Tech | 94 | 1.2M | AyusCare 612.7K | |
| Infectious Diseases | 7 | 997.5K | Mylab CoviSelf 988.3K | |
| In Vitro Diagnostics | 3 | 997.2K | Mylab Retailer 8.7K | |
| Healthcare It | 42 | 805.3K | Sanket Life-ECG,Stress,Fitness 66.1K | |
| Clinical Labs It | 19 | 650.7K | Samplify Sarthi Logistics 18.2K | |
| Genomics | 24 | 398.5K | Gold Club 106.8K | |
| Field Crops | 9 | 304K | Subeej 73.4K | |
| Disease Self Management | 20 | 299.4K | Dr Morepen Sync Sugar & BP App 244.5K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 125 of 225 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
207 companies hiring · $2B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Parexel has acquired pharmaceutical operations software vendor Vitrana.
Thermo Fisher Scientific said it has signed a definitive agreement to sell its microbiology business to Astorg, a pan-European private equity firm, for consideration of approximately $1.075 billion.
Hindustan Unilever’s acquisition of the residual 49% stake in plant-based nutrition brand OZiva, valuing the D2C brand at about ₹1,682 crore.
Nykaa has already acquired brands like Nudge Wellness and Dot & Key skincare to enhance its portfolio in the beauty retail space.
"Fullife Healthcare raised $31.62 million."
USV Private Ltd acquired around a 79% stake in nutraceutical firm Wellbeing Nutrition in an all-cash deal valuing the company at ₹1,583 crore in February.
The acquisition has been executed via a Business Transfer Agreement (BTA), marking Eris Lifesciences’ strategic expansion into the growing probiotics and microbiome-based therapeutics segment.
Robotic neuro-rehabilitation startup, Rymo Technologies, raised over ₹10 crore in a seed round led by IAN Angel Fund.
Kedaara Capital, the homegrown private equity firm ... is preparing to sell Universal NutriScience (UNS).
SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII ), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that on March 6, 2026, the Company completed a private placement of its common stock (the “Private Placement”) which generated approximately $18.6 million in gross proceeds, before deducting offering expenses.
Top 10 categories among 531 recorded events in the 24-month window.
12 companies with recorded IPO activity
IPO · BSE and NSE7 reports
IPO1 reports
IPO · BSE (NSE)2 reports
IPO3 reports
IPO1 reports
IPO · NASDAQ2 reports
IPO1 reports
IPO1 reports
11 tracked people moves
Appointment Group Chief Executive Officer
Appointment Chief Executive Officer
Departure Previously Vice President of Growth
Appointment Group Chief Financial Officer
Departure Previously Executive Vice President
Promotion Chairman and Chief Executive Officer
Promotion President and Chief Operating Officer
Promotion Executive Director of Research & Development and Commercialization
16 recorded customer wins
Customer: stada arzneimittel agHealthcare
Customer: Sathya Sai InstituteHealthcare
Customer: Tata TrustHealthcare
Customer: US Department of Defense
Customer: biofactura
Customer: cerecoE-commerce logistics
2 companies with reported reductions
1.0% rolescost reduction
11.0% rolescost reduction
12 recorded events
identified counterfeit packagingRegulators in India
rejected reference to 2023Health Authorities in Australia
identified packaging anomaly in batch #KA 24014Indian regulators and law enforcement agencies
issued urgent public health alert warning travellersAustralian Technical Advisory Group on Immunisation (ATAGI)
2 tracked suits
depreciation on goodwill and business/commercial rights under Income Tax Act 1961Regulatory · Settled
patent coverage of XolairCivil · Ongoing
Reported company results in the recorded window.
Median across 65 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| parexel→Vitrana ↗ | Announced | 2026-05-01 | Not stated in snapshot |
| astorg→Thermo Fisher Scientific ↗ | Announced | 2026-04-27 | $1.1B |
| USV→Wellbeing Nutrition ↗ | Announced | 2026-04-21 | Not stated in snapshot |
| hindustan unilever→OZiva ↗ | Announced | 2026-04-21 | Not stated in snapshot |
| marico→Plix ↗ | Completed | 2026-04-17 | Not stated in snapshot |
| nykaa→Nudge Wellness ↗ | Announced | 2026-04-07 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
2,150 postings in the preceding 12 months. The full 2,657-posting snapshot covers 155 employers.
15 tracked postings mention remote work.
1,393 postings specify a level.
Top skills across 2,657 tracked postings in the available jobs snapshot.
Median across 149 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Employees |
|---|---|
| Serum Institute of India ↗ | 6,537 |
| Cochlear ↗ | 4,773 |
| DentCare ↗ | 3,782 |
| Indian Immunologicals ↗ | 1,752 |
| LifeCell ↗ | 1,188 |
| Nuziveedu Seeds ↗ | 1,136 |
| SMT ↗ | 1,041 |
| Molbio Diagnostics ↗ | 649 |
2,221 founders and chief executives across 1,595 companies.
Ex-Organic Response, Boral, BCG · University of Sydney BE 1990, Stanford University Graduate School of Business MBA 1996
Founder Emerge Ventures, Co-Founder GenomeAsia 100K. IIT Madras B.Tech 1993, IIM Calcutta MBA 1995
Co-Founder-PharmEasy, API Holdings · Ex-Co-Founder-DIAL HEALTH CARE INDIA · IIM Ahmedabad MBA 2012
Ex-Myntra, Mu Sigma · IIT Madras BTech 2008, Indian School of Business MBA 2014
University of Leeds BS 2008
CEO Capp Aps, Neuation Technologies, Fine Care Biosystems. L M College of Pharmacy BPharm 1989
Ex-Barclays, American Express, J.P. Morgan. IIT Varanasi BTech 2009, SGH Warsaw School of Economics 2011, Management Development Institute…
Ex-Shasun · Anna University Chennai BTech 2000, Northwestern University MSc 2001
Ex-Tribune, American Express, Ago Synthesis · IIT Kharagpur BTech 2000, PhD 2006
Co-Founder & CEO-Pandorum MSU Baroda MSC 2005, IISc PhD 2012
Ex-Cellworks Research India, Magma Design Automation India, Monterey Design Systems, Cadence Design Systems. Anna University Chennai BE 1986…
Goapptiv, ex-Health Care Industry, ex-Pfizer, Indian Institute of Technology, Bombay, 2018
282 profiles with education records.
24 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
42,125 articles in the measured 12-month window.
Life Sciences coverage across India · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 18,615 |
| 2021Q3 | 11,843 |
| 2021Q4 | 8,934 |
| 2022Q1 | 9,602 |
| 2022Q2 | 8,953 |
| 2022Q3 | 9,184 |
| 2022Q4 | 10,410 |
| 2023Q1 | 10,556 |
| 2023Q2 | 9,701 |
| 2023Q3 | 9,959 |
| 2023Q4 | 9,069 |
| 2024Q1 | 9,204 |
| 2024Q2 | 9,449 |
| 2024Q3 | 10,771 |
| 2024Q4 | 11,824 |
| 2025Q1 | 13,334 |
| 2025Q2 | 9,173 |
| 2025Q3 | 10,740 |
| 2025Q4 | 10,171 |
| 2026Q1 | 11,560 |
Article volume measures coverage, not market sales.
857 recorded company events across 106 companies; percentages use that event total.
Life Sciences coverage across India · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across India
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| generic drug approval | 892 | 558 | 60% |
| drug distribution | 465 | 311 | 50% |
| innovator drug patents | 251 | 160 | 57% |
| drug patent exclusivity | 215 | 140 | 54% |
| drug safety monitoring | 213 | 109 | 95% |
| medication patent litigation | 213 | 136 | 57% |
| regulatory inspection | 187 | 115 | 63% |
| drug repurposing ai | 179 | 117 | 53% |
| diagnostic biotechnology | 150 | 88 | 70% |
| commodity futures | 134 | 45 | 198% |
| core inflation rate | 414 | 704 | -41% |
| inflation analysis | 293 | 464 | -37% |
| headline inflation | 185 | 295 | -37% |
| test cricket | 62 | 289 | -79% |
| stock indices | 113 | 261 | -57% |
Life Sciences coverage across India
monetary stance shift, core inflation rate, monetary easing
59.0% critical · 35.0% positivepre-ipo valuation, ipo prospectus, ipo pricing
52.0% critical · 47.4% positivemonetary stance shift, core inflation rate, monetary easing
42.0% critical · 44.4% positiveLife Sciences coverage across India. Topic labels describe recorded classifications and can include broad context.
2,919 papers in the recorded india scope.
Tone counts: 2,706 positive · 84 neutral · 129 negative.
Landmark: Crops that feed the world 6. Past successes and future challenges to the role played by maize in global food security
Landmark: Advances in Edible Coatings for Fresh Fruits and Vegetables: A Review
Landmark: Biomedical photoacoustic imaging
Common problems researchers identify · 0117.9% of this theme group
Researchers highlight risks in food safety, processing, and population nutrition, emphasizing need for sustainable management.
Food safety (11) · Population (9) · Food processing (6) · Food security (11)
Aflatoxins: A Global Concern for Food Safety, Human Health and Their Management
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 447.9 |
| 2023 | 423.1 |
| 2024 | 327.8 |
| 2025 | 338.6 |
Common problems researchers identify · 0216.8% of this theme group
Papers discuss difficulties in replicating phytochemical extraction and drug development from medicinal plants.
Medicinal plants (10) · Drug (9) · Phytochemical (6) · Replication (4)
Significance of Antioxidant Potential of Plants and its Relevance to Therapeutic Applications
Foundations of Phytochemistry: Isolation, Characterization and Bioactive Potential of Medicinal Plants
| Year | Share index |
|---|---|
| 2022 | 156.0 |
| 2023 | 148.6 |
| 2024 | 147.8 |
| 2025 | 178.2 |
Common problems researchers identify · 0316.0% of this theme group
Studies point to technical hurdles in bioprocessing, synthetic biology, and sustainable biofuel production.
Biomass (8) · Bioprocess (4) · Biofuel (4) · Synthetic biology (4)
Antimicrobial active packaging with biopolymers and natural extracts: sustainable solutions and technological challenges
Phytochemical profiling and pharmaceutical exploitation of indigenous vegetables: Extraction technologies and therapeutic potential
| Year | Share index |
|---|---|
| 2022 | 49.6 |
| 2023 | 48.0 |
| 2024 | 50.4 |
| 2025 | 53.3 |
Common problems researchers identify · 0415.2% of this theme group
Authors note constraints in germplasm improvement, trait stability, and disease impact on yields.
Crop (11) · Agriculture (17) · Germplasm (5) · Trait (4)
Disease Impact on Wheat Yield Potential and Prospects of Genetic Control
Successes, constraints, and prospects for sustainable dairy cattle breeding using artificial insemination technology in Tanzania. A brief re
| Year | Share index |
|---|---|
| 2022 | 1634.8 |
| 2023 | 1662.7 |
| 2024 | 1794.6 |
| 2025 | 1993.0 |
Common problems researchers identify · 0513.5% of this theme group
Research flags rising antimicrobial resistance and the need for new defensive strategies.
Antibiotic resistance (34) · Antibiotics (18) · Antimicrobial (19) · Resistance (9)
Antimicrobial Resistance
Microbiological Innovations as a Defence Against Antimicrobial Resistance
| Year | Share index |
|---|---|
| 2022 | 882.3 |
| 2023 | 835.4 |
| 2024 | 912.9 |
| 2025 | 968.7 |
Common problems researchers identify · 0611.6% of this theme group
Works identify challenges in applying nanotechnology and other methods for long‑term food security.
Agriculture (22) · Food security (16) · Sustainability (12) · Sustainable agriculture (6)
Nanotechnology in Sustainable Agriculture: Recent Developments, Challenges, and Perspectives
Nanoparticle-Based Sustainable Agriculture and Food Science: Recent Advances and Future Outlook
| Year | Share index |
|---|---|
| 2022 | 1508.8 |
| 2023 | 1556.1 |
| 2024 | 1734.9 |
| 2025 | 1957.8 |
Common problems researchers identify · 079.1% of this theme group
Papers examine how abiotic factors and rhizosphere interactions affect plant resilience.
Abiotic stress (7) · Abiotic component (7) · Rhizosphere (5) · Gut flora (5)
Salicylic acid-induced abiotic stress tolerance and underlying mechanisms in plants
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 103.0 |
| 2023 | 88.5 |
| 2024 | 80.7 |
| 2025 | 79.4 |
Cautions · 0136.2% of this theme group
Authors urge careful evaluation of new antimicrobial and antifungal approaches before widespread use.
Antimicrobial (5) · Antibiotic resistance (5) · Resistance (3) · Antifungal (3)
Postbiotics-parabiotics: the new horizons in microbial biotherapy and functional foods
Essential Oils as Antimicrobial Agents Against WHO Priority Bacterial Pathogens: A Strategic Review of In Vitro Clinical Efficacy, Innovatio
| Year | Share index |
|---|---|
| 2022 | 506.0 |
| 2023 | 490.4 |
| 2024 | 537.6 |
| 2025 | 633.8 |
Cautions · 0232.5% of this theme group
Studies caution about uncertain health benefits and shelf‑life issues of nutraceuticals.
Nutraceutical (4) · Human health (3) · Health benefits (3) · Shelf life (2)
Advances in Edible Coatings for Fresh Fruits and Vegetables: A Review
Biofortification of horticultural crops for improving human nutrition and health
| Year | Share index |
|---|---|
| 2022 | 182.2 |
| 2023 | 190.4 |
| 2024 | 222.4 |
| 2025 | 283.4 |
Cautions · 0325.0% of this theme group
Research warns of DNA damage and oxidative stress linked to certain interventions.
DNA damage (4) · Trait (3) · Oxidative stress (2) · Genotype (2)
Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies
Mechanisms of genotoxicity. A review of<i>in vitro</i>and<i>in vivo</i>studies with engineered nanoparticles
| Year | Share index |
|---|---|
| 2022 | 193.3 |
| 2023 | 213.5 |
| 2024 | 156.0 |
| 2025 | 153.1 |
Cautions · 046.2% of this theme group
Papers highlight gaps in analytical methods and stress response interpretations.
Analytical Methods for Identification and Quantification of Quinoa Saponins: A Review
Salinity responses and tolerance mechanisms in sugarcane (Saccharum officinarum L.): Recent updates and future perspectives
Opportunities · 0121.4% of this theme group
Investigations explore how modulating gene expression can trigger apoptosis and cytotoxic effects.
Downregulation and upregulation (26) · Apoptosis (21) · Gene (50) · Cytotoxicity (22)
Apoptotic and Anti-Proliferative Potential of Spirulina platensis Methanolic Extract Against the Human Breast Cancer Cell Line MDA-MB-231: A
Methylation and Expression Analysis of POU4F2, HOXA9, RBM46, and TSGA10 Genes in Bladder Cancer Using Methyl-Sensitive Restriction Enzyme PC
| Year | Share index |
|---|---|
| 2022 | 2551.8 |
| 2023 | 2558.4 |
| 2024 | 2223.7 |
| 2025 | 1754.8 |
Opportunities · 0214.6% of this theme group
Research shows promise in using microbes and their metabolites to control plant diseases.
Antimicrobial (52) · Fungicide (21) · Antibiotic resistance (26) · Biological pest control (22)
Harnessing secondary metabolites of endophytic microbes: a next-generation biopesticide for crop disease management
Harnessing secondary metabolites of endophytic microbes: a next-generation biopesticide for crop disease management
| Year | Share index |
|---|---|
| 2022 | 520.6 |
| 2023 | 505.2 |
| 2024 | 549.6 |
| 2025 | 646.4 |
Opportunities · 0314.5% of this theme group
Studies reveal benefits of fermented feed ingredients for animal growth and nutrient utilization.
Feed conversion ratio (22) · Broiler (17) · Nutrient (31) · Fermentation (27)
Effect of Dietary Supplementation of Mushroom (Agaricus bisporus) Fruiting Body Waste Powder on Growth Performance, Nutrient Utilization and
Millet Fermentation: Biochemical Transformations, Health Impacts, and Enhanced Nutritional Profiles
| Year | Share index |
|---|---|
| 2022 | 127.8 |
| 2023 | 120.4 |
| 2024 | 117.4 |
| 2025 | 127.7 |
Opportunities · 0413.3% of this theme group
Works focus on integrating genomics and breeding to improve drought tolerance and food security.
Agriculture (75) · Crop (45) · Abiotic stress (26) · Food security (28)
Integrated genomics, physiology and breeding approaches for improving drought tolerance in crops
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 1659.3 |
| 2023 | 1678.3 |
| 2024 | 1809.0 |
| 2025 | 2006.7 |
Opportunities · 0512.8% of this theme group
Papers discuss green synthesis and valorization of agri‑food by‑products for biofuel and biotech.
Sustainability (45) · Production (24) · Biomass (18) · Biofuel (14)
Advances in green synthesis of nanoparticles for biomedical applications: Antimicrobial, antiviral, and cancer therapies
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 228.1 |
| 2023 | 249.5 |
| 2024 | 309.6 |
| 2025 | 432.8 |
Opportunities · 0612.8% of this theme group
Research emphasizes leveraging germplasm variability to boost crop productivity.
Heritability (37) · Germplasm (45) · Genetic diversity (32) · Yield (41)
Assessment of Genetic Variability for Yield-Related Traits in Lentil (Lens culinaris Medik.) Germplasms
Genetic Variability and Heritability of Maize Yield in Diverse Inbred Lines: Implications for Economically Efficient Breeding
| Year | Share index |
|---|---|
| 2022 | 65.5 |
| 2023 | 58.4 |
| 2024 | 52.1 |
| 2025 | 60.1 |
Opportunities · 0710.5% of this theme group
Studies highlight medicinal plants and nutraceuticals as sources of health‑promoting compounds.
Phytochemical (43) · Medicinal plants (31) · Nutraceutical (33) · Health benefits (32)
Phytochemistry, pharmacology, and traditional uses of beverage plants with dietary hormetic potential for human health
Leveraging Medicinal Herbs and Fruits for Functional Dairy: A Review of Phytochemistry, Technology, and Health Outcomes
| Year | Share index |
|---|---|
| 2022 | 68.7 |
| 2023 | 64.3 |
| 2024 | 60.5 |
| 2025 | 87.9 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 49.0% | 37.5% |
| Descriptive | 19.3% | 17.6% |
| Breakthrough | 12.8% | 26.1% |
| Problem-identifying | 12.6% | 9.8% |
| Cautionary | 2.9% | 4.2% |
| Comparative | 2.7% | 3.9% |
| Critical | 0.7% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Hardware, e-waste & supply chainFruit and Vegetable Waste: Bioactive Compounds, Their Extraction, and Possible Utilization | 5 | 0.18% | 0 (0.0%) | 0.15% |
| Privacy & surveillanceArtificial intelligence and internet of things enabled systems for smart veterinary disease detection | 3 | 0.11% | 1 (33.3%) | 0.21% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Safety & misuse | 0 | 0.0% | 0 (%) | 0.01% |
| Bias & fairness | 0 | 0.0% | 0 (%) | 0.03% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: India. This may be broader than the company geography.
Compare demand signals in India’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Air pollution ↗Environmental Driver | 50.0 | 10.0 | +40.0 | -0.0% | |
| Infectious outbreaks ↗Disease Burden | 35.7 | 10.0 | +25.7 | +4.8% | |
| Layoffs & income shocks ↗Spending Pressure | 57.1 | 40.0 | +17.1 | +77.0% | |
| Maternal & child health ↗Disease Burden | 64.3 | 80.0 | -15.7 | +58.6% | |
| Cancer burden ↗Disease Burden | 28.6 | 60.0 | -31.4 | +50.5% | |
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 50.0 | 100.0 | -50.0 | +94.6% | |
| Mental health ↗Disease Burden | 64.3 | — | No matching category | — | +54.5% |
| Ageing & elder care ↗Disease Burden | 50.0 | — | No matching category | — | +82.4% |
Showing all 8 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. India is highlighted.
Each city’s reading is a share of its own coverage.
Air pollution · Mental health · Layoffs & income shocks
Mental health · Air pollution · Maternal & child health
Mental health · Maternal & child health · Infectious outbreaks
Mental health · Air pollution · Diabetes, hypertension & cardiac burden
Mental health · Infectious outbreaks · Maternal & child health
Mental health · Air pollution · Maternal & child health
Mental health · Infectious outbreaks · Layoffs & income shocks
Mental health · Maternal & child health · Infectious outbreaks
Mental health · Infectious outbreaks · Maternal & child health
Mental health · Maternal & child health · Cancer burden
Mental health · Air pollution · Infectious outbreaks
Mental health · Infectious outbreaks · Maternal & child health
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 1204 | 23.58 |
| 2024Q4 | 3994 | 78.86 |
| 2025Q1 | 1393 | 29.69 |
| 2025Q2 | 539 | 14.29 |
| 2025Q3 | 847 | 17.56 |
| 2025Q4 | 3710 | 99.76 |
| 2026Q1 | 1186 | 25.13 |
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 684 | 13.4 |
| 2024Q4 | 355 | 7.01 |
| 2025Q1 | 831 | 17.71 |
| 2025Q2 | 398 | 10.55 |
| 2025Q3 | 796 | 16.51 |
| 2025Q4 | 394 | 10.59 |
| 2026Q1 | 389 | 8.24 |
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 372 | 7.29 |
| 2024Q4 | 229 | 4.52 |
| 2025Q1 | 324 | 6.91 |
| 2025Q2 | 347 | 9.2 |
| 2025Q3 | 591 | 12.25 |
| 2025Q4 | 387 | 10.41 |
| 2026Q1 | 423 | 8.96 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 456 | 8.93 |
| 2024Q4 | 369 | 7.29 |
| 2025Q1 | 366 | 7.8 |
| 2025Q2 | 376 | 9.97 |
| 2025Q3 | 722 | 14.97 |
| 2025Q4 | 440 | 11.83 |
| 2026Q1 | 504 | 10.68 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 196 | 3.84 |
| 2024Q4 | 272 | 5.37 |
| 2025Q1 | 331 | 7.05 |
| 2025Q2 | 206 | 5.46 |
| 2025Q3 | 366 | 7.59 |
| 2025Q4 | 307 | 8.25 |
| 2026Q1 | 379 | 8.03 |
Chronic cardiometabolic burden can turn into decades of management demand per patient.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 141 | 2.76 |
| 2024Q4 | 137 | 2.7 |
| 2025Q1 | 154 | 3.28 |
| 2025Q2 | 213 | 5.65 |
| 2025Q3 | 325 | 6.74 |
| 2025Q4 | 263 | 7.07 |
| 2026Q1 | 164 | 3.48 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 1150 | 22.52 |
| 2024Q4 | 1075 | 21.22 |
| 2025Q1 | 1276 | 27.19 |
| 2025Q2 | 974 | 25.83 |
| 2025Q3 | 1964 | 40.72 |
| 2025Q4 | 1419 | 38.16 |
| 2026Q1 | 1418 | 30.05 |
An ageing base can shift demand toward geriatric, home and chronic care.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 154 | 3.02 |
| 2024Q4 | 191 | 3.77 |
| 2025Q1 | 234 | 4.99 |
| 2025Q2 | 222 | 5.89 |
| 2025Q3 | 373 | 7.73 |
| 2025Q4 | 238 | 6.4 |
| 2026Q1 | 334 | 7.08 |
India life sciences coverage
BMC Microbiology
494 citations in the snapshot
Indian Journal of Ophthalmology
407 citations in the snapshot
Cureus
341 citations in the snapshot
Emerging infectious diseases
326 citations in the snapshot
India coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| frailty hypertension | 60 | 22 | 205.4% |
| exercise fatigue oncology | 56 | 22 | 185.1% |
| hypertensive cardiomegaly | 61 | 25 | 173.2% |
| geriatric deaths | 48 | 20 | 168.8% |
| crib death | 57 | 24 | 166.0% |
| negligence fatalities | 49 | 22 | 149.4% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
25.3% across the displayed hubs
56 companies hiring · $1.0B disclosed funding
Explore companies in Bengaluru ↗
15.2% across the displayed hubs
22 companies hiring · $27.5M disclosed funding
Explore companies in Delhi ↗
14.8% across the displayed hubs
29 companies hiring · $938.8M disclosed funding
Explore companies in Mumbai ↗
14.7% across the displayed hubs
36 companies hiring · $177.5M disclosed funding
Explore companies in Hyderabad ↗
8.6% across the displayed hubs
19 companies hiring · $140.1M disclosed funding
Explore companies in Chennai ↗
8.3% across the displayed hubs
16 companies hiring · $59.4M disclosed funding
Explore companies in Pune ↗
7.9% across the displayed hubs
22 companies hiring · $26.1M disclosed funding
Explore companies in Ahmedabad ↗
5.2% across the displayed hubs
17 companies hiring · $59.8M disclosed funding
Explore companies in Gurugram ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 6 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗